These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24883440)

  • 1. Riociguat recommended by CHMP for approval in the EU for use in two forms of pulmonary hypertension.
    Dowdall M
    Future Cardiol; 2014 Mar; 10(2):163. PubMed ID: 24883440
    [No Abstract]   [Full Text] [Related]  

  • 2. Recruitment of pulmonary hypertension patients for PATENT trial with Riociguat [corrected] completed Sub-Saharan pulmonary hypertension study launched.
    Aalbers J
    Cardiovasc J Afr; 2012 Mar; 23(2):120. PubMed ID: 22447482
    [No Abstract]   [Full Text] [Related]  

  • 3. Riociguat for pulmonary hypertension.
    Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
    Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat for the treatment of pulmonary hypertension.
    Hambly N; Granton J
    Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Targeted therapy of pulmonary arterial hypertension (PAH)].
    Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
    [No Abstract]   [Full Text] [Related]  

  • 7. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Belik J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pulmonary hypertension].
    Kovacs G; Olschewski H
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2026-8. PubMed ID: 23023615
    [No Abstract]   [Full Text] [Related]  

  • 9. Changing perceptions in pulmonary hypertension.
    Gerges C; Lang IM
    Lancet Respir Med; 2014 Jan; 2(1):21-3. PubMed ID: 24461891
    [No Abstract]   [Full Text] [Related]  

  • 10. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
    Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C;
    N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat approved for pulmonary hypertension.
    Traynor K
    Am J Health Syst Pharm; 2013 Nov; 70(22):1960. PubMed ID: 24173000
    [No Abstract]   [Full Text] [Related]  

  • 12. New insights into pulmonary hypertension.
    Furlow B
    Lancet Respir Med; 2013 Sep; 1(7):508. PubMed ID: 24461605
    [No Abstract]   [Full Text] [Related]  

  • 13. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Larche NE; Mousa SA
    Drugs Today (Barc); 2013 Dec; 49(12):761-8. PubMed ID: 24524094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat for pulmonary hypertension.
    Cannon JE; Pepke-Zaba J
    Expert Rev Clin Pharmacol; 2014 May; 7(3):259-70. PubMed ID: 24580082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riociguat (Adempas). Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity.
    Prescrire Int; 2015 Nov; 24(165):265-6. PubMed ID: 26688897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
    Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
    Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
    Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
    Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The SERAPHIN study].
    D'Alto M; Vitulo P
    G Ital Cardiol (Rome); 2015 Jan; 16(1):6-10. PubMed ID: 25689745
    [No Abstract]   [Full Text] [Related]  

  • 20. Riociguat for the treatment of pulmonary hypertension.
    Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
    Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.